1. Medtech Insight

Minute Insight: Inivata's RaDaR Assay Study Yields Encouraging Results

 
• By Barnaby Pickering

RaDaR, a test for head and neck squamous cell carcinoma, demonstrated high efficacy in a new study.

Minute Insight
• Source: Informa/Alamy

Inivata has moved one step closer to the full commercialization of its RaDaR assay, which can detect 48 subvariants of tumor DNA, with the publication of clinical validation data from its LIONESS study.

The trial took blood samples from 17 patients with stage III-IVB, p16-negative head and neck squamous cell carcinoma who had previously received surgery to remove the tumors. The purpose was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.